



# Measuring the return from pharmaceutical innovation 2012

## Is R&D earning its investment?



# Contents

---

Foreword	1
Executive summary	2
Part 1. Peer benchmarks	4
Part 2: Strategies for transforming returns	14
Part 3: Conclusions	17
Appendix 1: Methodology	18
Notes	27
Glossary	28
Contacts	30

---

## **The Deloitte Centre for Health Solutions**

The Deloitte Centre for Health Solutions, part of Deloitte UK, generates insights and thought leadership based on the key trends, challenges and opportunities within the healthcare and life sciences industry. Working closely with other centres in the Deloitte network of member firms, including the US centre in Washington, our team of researchers develop ideas, innovations and insights that encourage collaboration across the health value chain, connecting the public and private sectors, health providers and purchasers, and consumers and suppliers.

The Thomson Reuters Life Sciences Professional Services team works with biopharmaceutical companies to provide new disease understanding, therapeutic and business insights, and better decision-support capabilities. Combining expert analysis in use of Thomson Reuters intelligent information assets, proprietary analytical and visualization tools, and deep expertise in the pharmaceutical and life sciences business Thomson Reuters clients benefit from tailored solutions that meet their unique business needs for faster, more informed decisions with higher confidence.

From discovery to launch and beyond, Thomson Reuters provides clients with the right data, information and insights, grounded in intelligent information to support clients in making the best decisions for their organizations.

# Foreword

Welcome to this Deloitte LLP report, the third in an annual series exploring the pharmaceutical industry's performance in generating a return from its investment in new product innovation.

In 2010 Deloitte LLP implemented a new research initiative in association with Thomson Reuters, quantifying the return on investment that the leading life sciences companies might expect to achieve from their late stage pipelines. This comprises the collection of assets most advanced in the development pipeline, either in Phase III, filed or submitted and therefore expected to launch within the next three to four years. The methodology assesses return on investment by using internal rate of return as the key metric. The research findings have stimulated constructive debate within the industry, and we are grateful for the feedback generated which has enhanced the methodology and analysis set out in this year's report. By mapping out three years of trend data, the 2012 report presents a richer set of insights into returns performance across the cohort of major R&D spenders.

Deloitte LLP and Thomson Reuters intend for this third report to provide a further opportunity for you to participate in and shape the discussion around return from investment in R&D. We hope that you and your colleagues find the research informative and thought-provoking, and welcome your further feedback and comments.



**Julian Remnant**  
R&D Advisory Partner,  
Deloitte LLP

**John Cole**  
Solutions Director, IP & Science,  
Thomson Reuters

# Executive summary

For the last three years, Deloitte LLP and Thomson Reuters have analysed the performance of the top 12 life sciences companies by estimating the projected financial returns from the investment in their late stage pipelines. The cohort of companies comprises the 12 publicly-listed companies reporting the highest absolute research and development (R&D) spend for 2008-09. The late stage pipeline includes those compounds which are either in Phase III development or submitted for approval.

Following feedback on the 2011 report, the methodology had been revisited and enhancements and improvements made to a number of elements including, the timing of when pipeline information is used for determining revenue forecasts, allocation of R&D cost between development phases and years, and other items which have a minor impact on margins. These enhancements have also been applied retrospectively, and the 2010 and 2011 results restated, so that findings from prior years are comparable with 2012.

Two key measures are explored: static internal rate of return (IRR), which provides a yearly 'snapshot' of returns performance, and dynamic returns, which provides a year-on-year assessment of the key drivers of changes in IRR over time. While there has been an overall decline in the static measure for the cohort, the decline appears to have stabilised, decreasing from 10.5 per cent in 2010, to 7.7 per cent in 2011, and 7.2 per cent in 2012. In 2012, a reduction in static returns was calculated for only half of the companies, relative to 2011, an increase for four companies and two show similar performance in 2012 relative to 2011. Last year, in the 2011 report, a reduction in static returns was calculated for 11 of the 12 companies compared to 2010.


It was noted in last year's report that ideally four to five years of dynamic R&D returns data are needed before supportable conclusions can be drawn on R&D productivity. Nevertheless, the evaluation of dynamic returns performance this year indicates that the strategies implemented by industry leaders over recent years may be starting to exert some positive influence on life sciences R&D productivity.

Comparing year-on-year changes in returns for the two time periods (2010-11 and 2011-12) highlights some encouraging trends between 2011 and 2012. Pipeline throughput, the number of new compounds entering the late stage pipeline and products progressing to commercialisation, has increased. In comparison to 2010-11, the volume and value of new compounds entering the late stage pipeline in 2011-12 has doubled. However, comparing the two time periods shows that while the number of approvals has increased by a third, the total sales value of all approvals has declined from \$309 billion to \$211 billion (revenue estimates over 21 years). Further areas to note in relation to R&D productivity are that the number and value of late stage terminations show no signs of abating, and existing compounds which continue to undergo late stage development in 2012 compared to 2011 have seen a net reduction of 17 per cent in their forecast revenues, possibly due to tougher market conditions.

Overall, the findings suggest a mixed performance picture in 2012 relative to 2011. The modelling suggests a gain in the value of new late stage innovation determined by the assets that have progressed into the cohort late stage pipeline this year compared to 2011. Conversely the cohort experienced a decline in the value realised from successful commercialisation over the same period. The cohort results, however, hide wide variations between companies. Of the 12 companies in the cohort, ten showed improvements in net pipeline replenishment, while only five recorded improvements in net commercial success.

In terms of underlying economics, the cost of developing an asset has remained relatively static while the likely revenues have declined. The cost of developing an asset, from discovery to launch, has increased slightly by four per cent from \$1,089 million in 2010 to \$1,137 million in 2012. Average inflow per asset is forecast to decline by 14 per cent relative to 2010, to reach a figure of \$2,166 million in 2012.

Market conditions for pharmaceutical companies are likely to continue to be challenging. Dynamics such as the US fiscal cliff, the potential that some countries might exit the eurozone, constraints around market access and pricing, changing patterns of demand and continuing downward pressure on healthcare budgets, present the industry with a volatile and highly uncertain economic environment in which to operate, let alone drive productivity improvements. These factors also present opportunities for growth, for example through the development of new business models, repurposing existing compounds and new ways of developing medicines. Those companies that seize these opportunities, while realising and sustaining an enhanced and competitive level of return from their investment in R&D, are likely to be the ones that thrive.



---

... our evaluation of dynamic returns performance this year indicates that the strategies implemented by industry leaders over recent years may be starting to exert some positive influence on life sciences R&D productivity.

# Part 1. Peer benchmarks

## Static snapshot

The static or yearly returns measure is a snapshot in time, for example the position as at 1 January 2010, 2011 or 2012. The modelling suggests that IRR cohort declined from 10.5 per cent in 2010, to 7.7 per cent in 2011 and then 7.2 per cent in 2012 (see Figure 1), equating to an overall reduction of 32 per cent across the three years. Most (27 per cent) of this reduction occurred between 2010 and 2011. For the period from 2011 to 2012 the percentage decline was seven per cent. The decline in the cohort's static internal rate of return (IRR) appears to be stabilising.


At an individual company level, there is wide variation in yearly returns across the cohort. More companies have exhibited an improvement or levelling off in yearly returns. In 2011, 11 of the 12 companies exhibited a decline in yearly returns performance compared with 2010. In 2012, this trend is changing, with four companies exhibiting an increase in yearly performance returns, two remaining relatively stable and half exhibiting a reduction in performance returns compared with 2011.

However, only two of the 12 companies analysed have a yearly performance return in 2012 that is higher than the original figure calculated in 2010.

There are several drivers of change in static IRR movements, primarily:

- terminations through either company originated termination or unsuccessful application for marketing authorisation
- stalled compounds which are not officially terminated but which are unlikely to launch, for instance due to the publication of unfavourable clinical trial data
- approvals due to commercialisation of late stage pipeline drugs
- changes in forecasts of existing late stage pipeline drugs, those that were present in the late stage pipeline in the previous year

Figure 1. Comparison of static IRR results, 2010-12



Companies labelled A to L consistent with prior year reports  
Source: Deloitte LLP and Thomson Reuters research

- new compounds entering the late stage pipeline between 1 January and 31 December for each year under investigation, 2010, 2011 and 2012
- changes in R&D costs over the ten years to 1 January 2010, 2011 or 2012.

To understand the impact of the changes in static returns the report, defined, measured and assessed the dynamic returns for the same cohort of companies over two time periods, 2010-11 and 2011-12.

#### **Dynamic returns measure 2010-12**

##### **There was a paucity of new compounds entering the late stage pipeline between 2010-11**

In last year's report it was identified that the key driver of a decline in year-on year returns between 2010 and 2011 was a loss of revenue captured in the late stage pipeline as products received regulatory approval and were launched (see Figure 2a). The increased revenue from new compounds entering the late stage pipeline was insufficient to balance revenue moving out of development into the commercial portfolio.

##### **Improvement in late stage pipeline replenishment between 2011-12**

For the period 2011 to 2012, new compounds entering the late stage pipeline provided a significant uplift to year-on-year returns (see Figure 2b). This was almost sufficient to offset the reductions due to approvals, terminations, stalled compounds and reductions in forecasts of existing compounds.

Small improvements in operating margin and reductions in licensing costs had a positive impact on year-on-year returns. At the same time an increase in overall R&D costs for the prior ten year period led to a negative impact on year-on-year returns.

Comparing year-on-year changes in returns for the two time periods highlights some positive trends including an influx of new compounds expecting to deliver solid returns, a continuing number of product approvals and improvements in operating margins. However, some elements continue to exert a strong negative influence on returns, for example reductions in forecasts for existing late stage compounds, compound terminations and increases in overall R&D cost.

#### **Pipeline momentum, 2010-11 and 2011-12**

Pipeline momentum analysis benchmarks the 12 companies, and the cohort as a whole, according to two criteria: net commercial success and net late stage pipeline refresh.

- Net commercial success is determined by assessing the impact of revenues associated with products that are successfully approved, offset against revenues lost due to terminations.
- Net late stage pipeline refresh is the sum of changes to the revenue forecasts for existing compounds, plus increases due to new compounds entering the late stage pipeline.


As can be seen from Figure 3, high performing companies are located in the upper top right quadrant (target quadrant) of the matrix. This quadrant represents a high level of net commercial success (high quality product approvals with few terminations) and a strong momentum into late stage pipeline (containing quality compounds with high commercial potential, few stalled compounds and high incremental revenues from new compounds).



Overall, our findings suggest a mixed picture of performance in 2012 relative to 2011. It will take a number of years for the full picture on R&D productivity to emerge and definitive conclusions can be drawn. The companies that are successful in the business of R&D will be effective in their validation of unmet need, in marshalling the best science and advances in diagnostics, and in deploying a flexible, collaborative development model that focuses early on gathering evidence of medical value.

## Pipeline momentum 2010-12


Figure 2a. Drivers of change in IRR 2010-11



See Glossary for definitions of factors used in this figure

Source: Deloitte LLP and Thomson Reuters research


Figure 4a. Pipeline momentum 2010-11



Company A not shown


Source: Deloitte LLP and Thomson Reuters research

Figure 2b. Drivers of change in IRR 2011-12



See Glossary for definitions of factors used in this figure  
 Source: Deloitte LLP and Thomson Reuters research

Figure 4b. Pipeline momentum 2011-12



Company A not shown

Source: Deloitte LLP and Thomson Reuters research

### Factors behind changes in pipeline momentum

Two specific areas were looked at to understand more clearly changes in pipeline momentum over time:

- number and value of late stage compounds
- trends in the number of terminations, approvals and new compounds.

### Number and value of late stage compounds

Late stage pipeline throughput has increased, with more compounds launching and more new compounds entering. Analysis shows that the number of late stage compounds within the cohort has remained relatively stable across the three years. Late stage asset numbers declined from 207 in 2010 to 186 in 2011, but then grew to 195 in 2012. However, the total forecast revenue of these compounds has gradually declined from \$1,369 billion in 2010 to \$1,049 billion in 2012. This suggests that the average forecast revenue per late stage compound has decreased for the cohort between 2010 and 2012.

### Terminations

Interestingly, we see an increase in the net movement of compounds through the late stage pipeline (see Figures 2a and 2b) which is apparent from changes in the number of terminations, approvals and new compounds across the two timeframes. Comparing 2010-11 and 2011-12, the number of terminations remained relatively static at 19 and 22, respectively. Revenue lost due to late stage terminations was \$73 billion in 2010-11 and \$77 billion in 2011-12.


### Product approvals

The number of product approvals increased by a third between the two time periods, 32 versus 41 respectively. While the number of approvals increased significantly, the total forecast revenue of these compounds decreased. The 32 approvals in 2010-11 accounted for forecast revenues of \$309 billion, the 41 in 2011-12 accounted for \$211 billion.

### New compounds

Behind improved pipeline strength is a doubling of the number of new compounds entering the late stage pipeline between the two time periods, from 35 in 2010-11 to 78 in 2011-12.

Figure 5. Average outflow and inflow per late stage pipeline asset, 2010-12



Source: Deloitte LLP and Thomson Reuters research

Encouragingly, the forecast risk adjusted revenue of these assets has also doubled, from \$193 billion in 2010-11 to \$378 billion in 2011-12. This may bode well in terms of arresting recent declines in R&D performance returns if the burgeoning late stage pipeline is commercialised at or above historical late stage success rates, and if the assets realise revenues broadly in line with current consensus forecasts.

### Margin and cost factors

#### The cost of bringing an asset to the late stage pipeline is broadly stable

Between 2010 and 2012, average outflows (linked to the R&D outlay to bring a compound from discovery to late stage development) have remained relatively constant, while average inflows (linked to forecast revenues) have declined (see Figure 5). The cohort average outflow per asset in 2012 was \$761 million. While this figure is not risk adjusted for late stage success rates, it does include the cost of failure associated with compounds in early R&D not progressing into the late stage pipeline. This represents an increase of six per cent, or \$42 million per asset, since 2010.

While the average outflow increased by 13 per cent between 2010 and 2011, it in fact decreased by six per cent between 2011 and 2012. Six of the 12 companies recorded a reduction in average outflow per asset between 2011 and 2012. There continues to be a wide variation in average outflow per asset between companies, ranging from \$216 million to \$1,794 million in 2012.

#### Average inflow per asset has declined

The cohort average inflow per asset in 2012 was \$2,166 million. This represents a decrease of 14 per cent, or \$351 million, since 2010. The decrease in 2010 to 2011 was eight per cent and in 2011 to 2012 it was seven percent. Three companies in the cohort recorded an increase in inflows per asset between 2011 and 2012. Again, there is wide variation between companies, inflows per asset range from \$1,013 million to \$4,086 million in 2012.

Inflows typically average three times the outflows required to bring the average asset to late stage pipeline. A change in inflow therefore has a higher impact on returns performance than a comparable change in outflow. Maximising inflows per asset delivers a significant uplift in returns performance.

---

The number of late stage compounds within the cohort has remained relatively stable across the three years ... However, the total forecast value of these compounds has gradually declined from \$1,369 billion in 2010 to \$1,049 billion in 2012.

**Table 1. Average R&D cost to develop a compound from discovery to launch (US\$ million)**

Company	Average cost per asset 2010	Average cost per asset 2011	Average cost per asset 2012	Change in average cost per asset 2010-12
<b>Cohort</b>	<b>1,089</b>	<b>1,235</b>	<b>1,137</b>	<b>4.4%</b>
A	1,803	3,229	1,657	-8.1%
B	481	470	315	-34.6%
C	844	1,150	822	-2.6%
D	1,792	2,075	2,822	57.5%
E	765	803	1,035	35.3%
F	886	1,026	1,065	20.2%
G	1,044	1,572	1,864	78.5%
H	1,887	2,376	1,905	1.0%
I	1,206	1,328	1,279	6.1%
J	1,045	853	1,105	5.7%
K	1,506	1,787	1,376	-8.6%
L	1,043	1,041	712	-31.7%

Source Deloitte LLP and Thomson Reuters research

**The cost of bringing an asset to launch has remained relatively stable from 2010 to 2012**

For the cohort of 12 companies, the average cost of developing an asset between 2010 and 2012 has increased by four per cent, from \$1,089 million in 2010, to \$1,137 million in 2012 (see Table 1).

However, between 2011 and 2012 the cost declined from \$1,235 million to \$1,137 million. There is wide variation between the 12 companies, however, over the three year timeframe five companies in the cohort recorded a reduction in this metric.

**Insights from year-on-year returns analysis**

Our analysis of year-on-year returns highlights mixed performance at both the company and cohort level.

The positive indications that suggest R&D is earning its investment:

- The value contribution due to new compounds entering the late stage pipeline for 2011-12 has more than doubled since the 2010-11 analysis.

- For the period 2011-12, the forecast revenues from new late stage pipeline compounds outweigh, by a factor of two, the value leakage from reduced revenue forecasts for existing products and late stage terminations. This is exerting a stabilising influence on the rate of IRR decline.
- Of the 12 companies analysed, two-thirds continue to perform well in terms of net commercial success. That is, they have generated more value from product commercialisation than lost from late stage terminations.
- At the cohort level, non-R&D costs continue to decline, resulting in a higher operating margin, helping to free up cash flow that could be reinvested in R&D.
- Of the 12 companies included in the cohort, ten have delivered an improvement in net late stage pipeline refresh, meaning that they have been effective in replenishing their late stage pipelines taking into account forecast revisions to existing compounds.

- In terms of performing consistently well on both elements of pipeline momentum, over half of the cohort now sits within the top right hand performance quadrant. Eleven of the 12 companies exhibited an improvement in at least one of the two pipeline momentum components.
- Over the three years from 2010 to 2012 the cost of developing a pharmaceutical asset has remained relatively constant; increasing by 13 per cent between 2010 to 2011, but decreasing by eight per cent between 2011 and 2012.

Less positive aspects of performance that R&D leaders will need to tackle:

- In the three years reviewed, there has been a decline in performance in the net commercial success elements. Seven of the 12 companies have seen a reduction in the value realised from market launches relative to late stage terminations. Companies need to perform well on both pipeline momentum components to deliver sufficient and consistent return on investment.
- The forecast inflows for each late stage pipeline asset continue to decline over time. Average inflows are approximately three times the average outflows per asset; therefore a decline in inflows can exert significant pressure on IRR.

- As the number of late stage pipeline assets has remained constant over the three years, the continued decline in inflows is putting pressure on the value of companies' late stage pipelines.
- The cohort seems to be making little headway in terms of reducing the number and value of late stage terminations. Earlier and more rapid decisions around terminations are key to driving improved returns performance, as is improving understanding of unmet need. Once a compound proceeds to late stage development, the cost of failure increases significantly. Repositioning or repurposing is one avenue that could be used to recoup a proportion of sunk R&D costs from failed compounds.

It is acknowledged that two years of year-on-year returns data is insufficient to provide a definitive view of performance. However, in contrast to last year's analysis, a convergence is seen in year-on-year returns across the cohort with respect to best in class performance.

---

**For the cohort of 12 companies the average cost of developing an asset between 2010 and 2012 has increased by four percent, from \$1,089 million in 2010, to \$1,137 million in 2012.**

# Part 2: Strategies for transforming returns

The research continues to highlight the need for the industry to sustain a relentless pursuit of improved R&D returns. The view is maintained that R&D leaders are generally pinpointing the right areas for change, and indeed some encouraging advances have been made since the 2011 report was published.

Yet, the opportunity to realise tactical performance gains from divesting unproductive capacity is diminishing, leaving R&D leaders the challenge of driving a more fundamental change in how they discover and develop new medicines.

Using Deloitte's Enterprise Value Map for R&D (Figure 6), areas that R&D leaders should focus on to transform the economics and business fundamentals of R&D are suggested. Some emerging opportunities to boost R&D returns that are expected to be observed over the coming years are described in this part of the report.

## Increase revenue


The analysis indicates that between 2010 and 2012 there has been a 14% decline in the average commercial value of a late stage asset across the cohort (as measured by average inflow). In this context, it is anticipated that R&D will continue its strive for more external focus throughout the value chain by:

- harnessing innovative opportunities regardless of origin, fostering external as well as internal innovation to drive up pipeline value
- improving payer, prescriber and patient relationships to improve line of sight between unmet need, clinical trial protocol and the economic, clinical and patient dimensions of effectiveness and value.

Access to progressive science and innovative drug candidates will be increased by:

- fully implementing the intent to reduce the distinction between internally and externally sourced innovation in capital allocation decision making
- using multiple approaches to increase the opportunities for harnessing external innovation, e.g. establishing early stage alliances, forming joint ventures or risk-sharing partnerships
- fostering 'knowledge spillover' between development teams by building a 'corporate innovation memory'.

Figure 6. Deloitte's Enterprise Value Map for R&D (abbreviated)



Source: Deloitte LLP research

Recent relevant developments on externalisation include:

- increased momentum behind the Structural Genome Consortium to enable access to external, non-industry sources of data and technology.<sup>1</sup>
- announcements of open innovation strategies that make internal data assets available to external researchers. One such example is that being implemented by GlaxoSmithKline.<sup>2,3</sup>
- introduction of new R&D operating models to facilitate access to external innovation hubs and increase the flexibility of R&D decision-making.<sup>4-9</sup>

Line of sight between unmet need, clinical research protocol and objectives for effectiveness and value will be improved by:

- identifying and factoring in regulator, patient and payer value criteria earlier in the R&D process and development strategy.
- using real world evidence to shape early development strategy and build an evidence-based, differentiated health economics case to payers. Electronic Health Records for Clinical Research (EHR4CR) and The Partnership to Advance Clinical electronic Research (PACeR) are examples of initiatives where the industry is working with health stakeholders to improve access to real world data, and are at the forefront of addressing some of the key challenges to harnessing the potential of real world evidence.<sup>10-12</sup>
- reconfiguring the development approach in anticipation of greater uptake of outcomes-based reimbursement. Drug developers that are adept in articulating the relative value of their products and in demonstrating a willingness to take on risk in meeting patient need cost effectively, will be seen as more differentiated and more closely aligned with payer needs, even if outcomes-based reimbursement is not consistently taken up by payers.
- adopting an agile governance approach that allows development programmes to adapt based on a continued dialogue with external stakeholders.

#### Reduce R&D unit costs

The analysis shows that in the 10 years to 1 January 2012, the average cost to develop a successful product from discovery to launch has increased slightly to \$1,137 million compared with the 10 year period to 1 January 2010, when the average cost was \$1,089 million (risk adjusted to take into account late stage success rates).

As pointed out in the 2011 report, the cost increase is despite a concerted effort by most of the industry to reduce R&D expenditure year on year. A large element of cost per successful launch is due to the 'sunk' investment in failed products. To date, R&D leaders have commonly looked at divesting unproductive capacity by outsourcing non-core functions to bring down fixed costs. This will remain a necessary, but insufficient strategy, to reverse the trend, and R&D leaders will need to look to transformational opportunities to reduce the cost of success by, for example:

- scaling up the union between drug research and molecular diagnostics to more widely yield companion assays that target treatment to specific patient populations and improve the downstream probability of success.
- collaborating with peers to remove duplication and overlaps in non-competitive capabilities in the form of people, processes, tools and facilities. The potential of 'cosourcing' was highlighted in the 2011 report, and it is encouraging to observe the subsequent formation in September 2011 of TransCelerate BioPharma, a nonprofit partnership between Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, J&J, Pfizer, Roche and Sanofi. The goal of TransCelerate is to streamline and standardise clinical trial infrastructure and methods globally, for instance, by collaborating on a database of worldwide clinical trial sites to facilitate site selection, minimize paperwork and accelerate clinical study conduct.<sup>13</sup>
- selectively exploring the repurposing or repositioning of failed assets to generate new or additional revenue from a molecule by targeting diseases other than those for which it was originally intended. Repositioning of launched or failed drugs has opened up a new source of revenue to large, medium and small life sciences companies as well as attracting venture capital funding. Products developed utilising repositioning strategies are predicted to generate up to \$20 billion in annual sales in 2012.<sup>14</sup> Pharmaceutical executives are expected to turn their attention more vigorously to repositioning strategies to maximise the value of existing assets.<sup>15</sup>

### Reduce R&D cycle times

A reduction in cycle times can be realised through more focussed governance, process improvement or more selective disease area strategies. Given the interdependency of revenue, cost and cycle times, approaches to reduce cycle times are typically realised in combination with approaches to either increase revenue and/or reduce R&D costs by:

- applying lean process improvement, to reduce the white space between development phases and shorten the critical path
- improve identification of clinical trial participants and investigator selection through developing and enhancing relationships with healthcare providers
- the use of digital technology to get closer to patients, and thereby accelerate clinical trial recruitment and reduce trial cost per patient
- selecting disease areas within the portfolio based on depth of scientific expertise and understanding, disease area cycle times, degree of unmet need, and market potential.


### Simulating returns improvement

In line with last year's analysis, an assessment (IRR simulation) was undertaken of a mid quartile company's performance, focussing on six high level R&D levers to identify the key priorities for the pharmaceutical industry (see Figure 7).

Similar to last year's results, the simulation shows that late stage success rates remain a key focus for the industry. A small percentage improvement in this lever will have greater impact on IRR than the other levers we evaluated. This confirms that quality of output, in terms of developing compounds that are most likely to achieve regulatory approval, remains of paramount importance to improving returns.

Interestingly, changes in revenue, R&D cost and margin all exert a comparable level of impact on yearly returns. In comparison to 2011, revenue and R&D cost now exert a greater level of impact. Both of these levers have experienced pressure over the last 12 months. Market austerity, challenges around healthcare budgets and pricing and reimbursement hurdles have dampened the ability of new product launches to deliver optimal sales revenues.

Figure 7. Change in value levers required for an increase or decrease in yearly returns of ten per cent



SG&A = Selling, general and administrative expenses  
See Appendix 1 for the sensitivity analysis methodology

Source: Deloitte LLP and Thomson Reuters research

# Part 3: Conclusions

Analysis of R&D performance in 2012 indicates that the decline in returns may be stabilising. In the 2011 report, 11 of the 12 companies exhibited a decline in returns. This year, half of the cohort has performed better than or similar to last year. In most cases this year-on-year improvement appears to be driven by an increase in the ability of the cohort to prime their late stage pipelines with assets that have a high technical and commercial probability of success.

Overall, the value released from the development portfolio to the commercial portfolio, at the cohort level, has declined over the last 12 months. However, the cohort average masks improvements at the individual company level; five of the cohort have shown an improvement in this element since last year.

An assessment of static returns provides a limited view of performance. More insight can be provided when static IRRs are viewed alongside the factors contributing to a change in IRR over time. Three years is insufficient to predict future developments with confidence, nevertheless the analysis reveals pointers on performance and areas in which industry leaders might concentrate their attention.

Signs that R&D returns could be improving:

- The elements of pipeline momentum are becoming more balanced; a doubling is recorded in the contribution from net pipeline replenishment in terms of both forecast value and volume of compounds. In addition, forecast revenues from these new compounds outweigh the value lost from late stage terminations and downward forecast adjustments for existing late stage pipeline compounds (compounds that were in late stage development last year and remain active in the cohort late stage pipeline this year).
- Across the cohort, over half of the companies perform well on both net commercial success and net pipeline refresh: they are generating more value from launches than terminations and are effectively priming their late stage pipelines with promising new compounds.

- Some cost elements have stabilised (development cost per asset) or declined (non-R&D costs) helping to improve operating margins and increasing cash available for R&D spend. There is a potential for these cost improvements to have a greater impact over time, as the methodology incorporates an inherent time lag and ten years of historical R&D costs are considered. Hence cost improvement programmes implemented in the last four to five years may have yet to achieve a full impact on the cost elements of the analysis.

Areas which continue to be of concern:

- The total forecast revenue potential of the cohort late stage pipelines continues to decline year on year. This is heavily influenced by a decline in the average forecast inflow per late stage asset and the marginal increase in the total number of late stage assets in 2012 compared to 2011.
- Little inroad appears to have been made to reduce the number and/or value of late stage terminations. Reducing the cost of failure continues to prove challenging.
- While the number of approvals has increased by approximately 30 per cent in the last twelve months, the forecast revenue that these approvals are expected to deliver has declined by 30 per cent. This has resulted in over half of the cohort declining in terms of the level of net commercial success. Time will tell whether the wave of new late stage compounds is able to realise the anticipated commercial potential at a higher probability of development success than has been achieved historically.

Overall, our findings suggest a mixed picture of performance in 2012 relative to 2011. It will take a number of years for the full picture on R&D productivity to emerge and definitive conclusions can be drawn. The companies that are successful in the business of R&D will be effective in their validation of unmet need, in marshalling the best science and advances in diagnostics, and in deploying a flexible, collaborative development model that focuses early on gathering evidence of medical value.

# Appendix 1: Methodology

Deloitte LLP in association with Thomson Reuters has built an interactive model to calculate the Internal Rate of Return (IRR) for the companies and compounds of interest. This section describes which companies and compounds are included, and details the methodology, model inputs, outputs and assumptions used to generate individual and cross-company IRR metrics.

## Company cohort

The analysis focuses on the same 12 companies that were included in the previous reports (published in 2010 and 2011); namely the top 12 publicly-listed research-based pharmaceutical and biotechnology companies measured by 2008-2009 R&D spend. These companies comprise: Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Roche, Sanofi and Takeda. The cohort is consistent for 2010, 2011 and 2012.

## Compounds evaluated

The IRR analysis focuses on each company's late stage pipeline defined as the set of compounds that are either in phase III development or submitted for approval as of April for each relevant year (2010, 2011 and 2012). The types of compound included in the late stage pipeline comprise:

- new chemical entities (NCEs)
- new biological entities (NBEs)
- significant line extensions – those expected to result in a measurable uplift in revenues
- reformulations.

For all compounds included in the late stage pipeline, their origin was assessed and they have been categorised as:

- self-originated
- in-licensed – acquired through a licensing agreement with a third party

- joint venture – actively being developed as part of a partnership agreement with one or more third parties
- acquired as part of a business combination, either a merger of two corporations or acquisition of one corporation by another.

## Methodology – Principles applied to the model

### Model refinements

Following feedback received the methodology has been revisited and enhancements and improvements made to a number of elements as detailed below. These enhancements have been applied retrospectively, and 2010 and 2011 results restated, so that findings from prior years are comparable with 2012.

### Changes to other margin impacting items, including the treatment of corporation tax

The average cash operating margin was calculated to apply to forecast revenues using reported operating profit using company specific data over a ten year period. In doing so judgements were applied, where applicable, to determine what is believed to be values reflecting normal activities. As a result of feedback from previous models certain of these judgements have been refined in 2012, which whilst minimal in nature, most notably impact corporation tax rates.

### Dates on which the late stage pipeline is determined

As part of the 2012 process inconsistencies were identified on the date on which companies' late stage pipelines were determined. While unlikely to result in significant changes, this date was aligned for all companies (April for each respective year), which is the date that the majority of companies had published their previous year's annual reports which include data on late stage pipelines. This date has been consistently applied for the two previous data sets (April 2011 for the 2011 report, and April 2010 for the 2010 report).

**Adjustments to R&D costs**

As described further below, R&D costs were allocated on the basis of industry average cycle times and cost distribution between development phases. This has been historically undertaken using a straightforward allocation model; in 2012 this was refined to eliminate any double counting and more appropriately allocate costs between years and development phases.

**Currency**

All calculations have been performed in US dollars. Where historic source data has been presented in currencies other than US dollars, it has been converted using the Financial Times yearly average rate for the relevant year. Where forward looking data is in currencies other than US dollars, the current Financial Times prevailing 12 month average rate has been used for conversion into US dollars.

**Taxation**

IRR has been calculated based on post tax inflows and outflows. Company specific tax rates have been calculated based on average effective tax rates over the 10 years to 31 December 2010, 2011 or 2012, adjusted for non-recurring items, such as litigation costs, impairments and in-process R&D expense.


**IRR calculation**

IRR is a measure which equates the cost of developing an investment and the expected benefits that the investment will deliver. The methodology assesses two IRR measures; yearly, snapshot returns performance and dynamic, year-on-year returns performance.

**Static IRR**

Figure 8 summarises the methodology used to calculate forecast performance returns and estimated costs. It equates cash outflows with cash inflows to generate an IRR value, with a separate IRR value generated for each of the three years under investigation, 2010, 2011 and 2012.

**Figure 8. Calculating yearly, static IRR**



Source: Deloitte LLP

Yearly, static IRR is calculated for a defined basket of late stage compounds by estimating the expenses associated with developing the compounds and the likely potential returns that they will deliver. This is achieved using estimates of each company's:

- Annual R&D expenses (cash outflows) for the prior 10 years – which calculates the cost associated with bringing the basket of compounds to a particular stage of development
- Annual risk adjusted revenues (cash inflows) forecast for the future 21 years – which estimate the likely returns that the basket of compounds will deliver.


Calculating the dynamic returns performance allows the movement in static, snapshot returns performance from one year to the next to be reconciled and also quantifies the key elements driving this change. It is calculated for two time periods; 2010-11 and 2010-12. Dynamic returns performance focuses on the same baskets of late stage pipeline compounds as yearly, snapshot returns performance, however, the basket of compounds changes year-on-year due to movement of compounds into and out of the late stage pipeline.

The elements driving a change in IRR can be categorised into two groups, based on whether they impact cash outflows or cash inflows.

**Dynamic (year-on-year) returns performance**

The methodology used to determine the drivers of year-on-year changes in returns performance is summarised in Figure 9.

**Figure 9. Determining the drivers of year-on-year dynamic returns**



### Cash outflow elements

The four outflow elements driving change in IRR comprise:

- R&D cost – changes to R&D costs for self-originated compounds
- cost phasing – changes to how R&D costs are allocated over the historical 10 year time period
- licensing – increases or decreases in licensing expenses associated with the basket of compounds under review
- tax rates – alterations to the company specific tax rates based on average effective tax rates over the historical 10 year period.

The annual impact of each factor on the cash outflows has been inputted into the models in isolation so that their individual impact on the IRR can be quantified, given constant inflows.

### Cash inflow elements

The six inflow elements driving change in year-on-year returns performance comprise:

- terminated – future revenues lost from the late stage pipeline due to termination of compounds through either company or regulatory termination
- approved – transfer of revenues to the commercial portfolio due to compounds leaving late stage pipeline and being launched
- existing – increases or decreases in forecast revenues for compounds which remain within the late stage pipeline
- new – revenues associated with new compounds entering the late stage pipeline
- stalled – revenues lost due to compounds which are not officially terminated but which are unlikely to launch, for instance due to the publication of negative clinical trial data
- margin – changes in a company's average cash operating margin.

The annual impact of each factor on the cash inflow has been inputted into the models in isolation so that their individual impact on the IRR can be quantified, given constant outflows.


### Model inputs: R&D cash outflows

For all compounds included within company late stage pipelines, the origin of the compound was assessed. Compounds were categorised as; self-originated, acquired through in-licensing, or acquired through a business combination.

### Self-originated compounds

1. R&D costs have been obtained from publicly available company reports results based on applicable GAAP at the time results were issued (either local GAAP applicable in the country of incorporation, IFRS or US GAAP).
2. R&D costs recognised through profit and loss accounts are assumed to equal cash flows, unless a non-cash expense is separately disclosed (e.g. an inprocess R&D charge recorded under US GAAP) in which case this has been excluded from the R&D cost.
3. Following a business combination, R&D costs include those of the enlarged group, in line with the publicly available company reports (see below for pre-acquisition costs).
4. The use of publicly available data limited the model to the use of industry average cycle times and cost allocation when calculating R&D costs over the ten year period. Benchmark data (Source: CMR International 2011 Pharmaceutical R&D Factbook) was used to allocate costs as shown in Figure 10. Compared with last year, industry average cycle times remained relatively unchanged; preclinical to Phase II increased from 4.7 to 5.1 years, and Phase III to launch decreased from 3.5 to 3.4 years. Cost allocation has changed as shown in Table 2. This methodology incorporates the cost of attrition of assets from the initial cohort at discovery to the late stage pipeline as at 1 January 2010, 2011 or 2012.
5. R&D costs have not been included within the model beyond 31 December 2011.

**Figure 10. Allocation of R&D costs and cycle times, 2012**



Source: CMR International 2011 Pharmaceutical R&D Factbook

**Table 2. Change in R&D cost allocation: 2010, 2011 and 2012**

R&D phase	2010 report	2011 report	2012 report
Discovery to first toxicity dose	25%	25%	28%
Preclinical to Phase II	20%	29%	33%
Phase III and submission	55%	46%	39%

Source: CMR International 2011 Pharmaceutical R&D Factbook

#### Compounds acquired through in-licensing

1. Where a compound included within the company late stage product portfolios has been in-licensed from a third party, any upfront payments have been included in the relevant year of acquisition.
2. In-licensing information was obtained from the Thomson Reuters Partnering deals database. In most cases financial information was limited due to the commercial sensitivity of deal information.
3. As publicly available data typically does not include the timing or quantum of future contingent payments, the total amount of these costs associated with the relevant in-licensed compound have been assumed to be incurred at their maximum potential amounts on commencement of sales of the compound.
4. Any costs expended in developing the product subsequent to the in-licensing have been included as per the internally developed compounds.

#### Compounds acquired as part of a business combination

1. R&D costs arising from compounds acquired as part of a business combination enacted by an entity have been included in the model if considered material to the calculation of IRR.
  - a. R&D costs incurred after the date of the business combination have been included as per the internally developed compounds noted above.
  - b. R&D costs incurred prior to the date of the business combination have been included separately in the model obtained from publicly available company reports results based on applicable GAAP at the time results were issued (either local GAAP applicable in the country of incorporation, IFRS or US GAAP).
2. Private companies acquired were not considered as access to the required financial data is not widely available.

3. The cost associated with the acquisition of a compound as part of a business combination has not been included as the acquired company's pre-acquisition R&D cost is included as per the internally developed compounds. Furthermore publicly available data does not typically include the fair value attributed to each of the compounds acquired.
4. Any costs expended in developing the product subsequent to the business combination have been included as per the internally developed compounds.

### Model inputs: Forecast cash inflows

#### Revenue forecasts

1. Company revenues were forecast for a 21 year time frame for each time period under investigation as follows:
  - a. 2010 models – revenues forecast from 1 January 2010 – 31 December 2030
  - b. 2011 models – revenues forecast from 1 January 2011 – 31 December 2031
  - c. 2012 models – revenues forecast from 1 January 2012 – 31 December 2032.
2. All revenue data was extracted by Thomson Reuters from Thomson Reuters' assets and calculated using consensus forecasts and proprietary modelling. Data consistency was checked with external data sources and websites for consistency and agreement with general market principles (e.g. [www.fiercebiotech.com](http://www.fiercebiotech.com)).
3. Revenue forecasts have been risk adjusted for phase III and submission success rates, specific to therapeutic areas (CMR International Global R&D metrics programme 1994-2010). The risk of a product being withdrawn once it has come to the market has not been assessed in this model. The risk of product withdrawal compared with the potential risk of failure during development is relatively small. Also the probability of post-launch withdrawal is highly variable dependent on a number of factors and is therefore difficult to model accurately.
4. Revenue streams were forecast using Thomson Reuters' 2012-2016 consensus forecast data, combined with a proprietary sales forecast model. This model used consensus forecast data as a basis in tandem with a weighted sales average of the previous three years of sales data and a factor to indicate the saturation of the market, to calculate the desired year's sales data. Sales uptake curves were modelled using this methodology combined with an assessment of a compound's individual characteristics (e.g. molecule type, indication, mechanism of action and target) to understand if a compound had high, medium or low sales potential.
5. Consensus sales data was obtained by end July 2012; therefore forecasted revenues are accurate as of this date.
6. After peak sales had been reached, standard erosion curves were applied dependent on the molecule type (e.g. small molecule or biologic); different erosion curves have been used for small molecules (chemical entities) and large molecules (biological entities). The use of different erosion curves reflects the stringent competition in the small molecules generic market where, in extreme cases, loss of sales can happen in a matter of weeks and months. On the other hand the arrival of biosimilars into the generics market place is likely to have a less profound effect around loss of sales for biologics.
7. Small molecule and biologic curves are as follows (please refer to Figure 11):
 

*For small molecules*

  - a. A five per cent decrease in sales two-three years prior to patent expiration
  - b. A ten per cent year on year decrease in sales for two years prior to patent expiration
  - c. Once patent expiration occurred a 50 per cent year on year decrease in sales for four years
  - d. A 25 per cent decrease in sales for one year
  - e. A ten per cent decrease in sales for two years
  - f. A five per cent decrease in sales from thereafter until 2032.


*For biologics*

- g. No decrease in sales to patent expiration
  - h. A two per cent decrease in sales for one year
  - i. A five per cent decrease in sales for two years
  - j. A nine per cent decrease in sales for one year
  - k. A ten per cent decrease in sales until 2032.
8. The anticipated introduction of biosimilars over the short and medium term is likely to be slow. This is due to a number of factors including the number of biologics on the market compared with small molecules and the need to prove bioequivalency for biosimilars. It is therefore assumed that erosion of biologics sales will be considerably smaller compared with that of small molecules.
9. Available patent information was extracted from Thomson Reuters Cortellis or Newport for Generics for each compound. A patent landscape for an individual compound can be extremely complex involving upwards of 20 patents varying in nature and geographic application.

To define patent expiration the following rules were applied to intellectual property records:

- a. The Newport Constraint Date (NCD) was given precedence based on patents for major markets (USA, Europe and Japan). This date is the expected date of generic entry based on the opinions of Newport analysts.
- b. Newport patent dates were also consulted: All patents relating to a compound were considered when defining patent expiry.
- c. Product patents were used as the primary source for definition of a patent expiry date.
- d. Where product patent information was inconclusive secondary patents were used to define patent dates.
- e. For reformulations and line extensions other patent types were used to understand where five year patent extensions were appropriate.

**Figure 11. Diagrammatic representation of small molecule and biologic sales erosion curves**



Source: Thomson Reuters

### Margin applied to forecast revenues

Inflows have been determined by applying an average cash operating margin to revenues over the forecast period.

1. The average cash operating margin has been calculated using reported operating profit over the ten years preceding each year, 2010, 2011 or 2012, adding back R&D expense and depreciation/amortisation, and deducting capital expenditure and non-recurring costs. No adjustment has been made for working capital.
2. Reported operating profits have been obtained from publicly available company reports based on applicable GAAP at the time results were issued (either local GAAP applicable in the country of incorporation, IFRS or US GAAP).
3. Depreciation and amortisation includes directly related impairment charges.
4. Non-recurring costs include litigation costs, profits or losses arising from the sale of businesses or fixed assets, restructuring costs and profits or losses from equity investments.
5. Where operating profits include finance costs, these have been excluded from the calculation.
6. Average cash operating profits over the ten year period used to estimate cash outflows are assumed to equate to future margins over the 21 year revenue forecast period.

### Sensitivity analysis

Sensitivity analysis was conducted across six high level R&D value levers to realise a ten per cent change in IRR.

- *Revenue*: to effect the revenue changes, inflow was increased or decreased by the same proportion each year, over the 21 year forecast revenue period.
- *Cost*: to effect the cost changes, outflow was increased or decreased by the same proportion each year over the ten year period.

- *Cycle times*: the effects of cycle time changes were calculated by altering the launch dates of the portfolio of assets and spreading the resultant costs and revenues over the altered periods. Thus the IRR is affected by both the change in forecast revenues and an alteration in the discounting profile.

- For decreased cycle times, overall costs were not changed, however the period over which they were incurred was shortened. Total revenues are increased to take into account the earlier launch dates of the portfolio of assets, by increasing the number of years of peak revenue.
- For increased cycle times, overall costs were not changed; however, the period over which they were incurred was increased. Peak revenues were decreased to take into account the later launch dates of the portfolio of assets.

- *Success rates*: sensitivity to success rates is analysed by varying late stage success rates by a constant factor across all products to effect the desired ten per cent increase or decrease in IRR.

### Modelling assumptions

The use of revenue forecast data and publicly available information regarding pipelines and deal information presents certain challenges and risks associated with the construction of revenue forecasts and distribution of R&D costs within the life sciences industry. These challenges and risks include, but are not limited to, the following:

1. The late stage pipeline is an accurate reflection of the pipeline, as of April 2010, 2011 or 2012. This incorporates all public information available at that date. There is often a lag in obtaining intelligence on product launches, particularly of line extension products, and intelligence on new Phase III compounds entering the late stage pipeline. This may mean products are removed from the pipeline the year following launch or may have a delay in pipeline inclusion until the year following Phase III entry.

2. Deal and licensing information is commercially sensitive and therefore exact financial information is limited. During the research phase several proprietary databases and publicly available information have been used to construct an accurate picture of the costs associated with compounds. It is important to note however that not all in-licensing and deal financial information is available outside of the companies involved, therefore some deal information used within this study does not have financial values associated with it.
3. The revenue and portfolio information provided in this paper constitute forward looking statements relating to the financial, operational and performance of specific companies. Although the authors of this paper believe these forward looking statements are based on reasonable assumptions listed here, any forward-looking statements by their very nature, involve risks and uncertainties. These forward-looking statements may be influenced by factors which affect actual outcomes or results to be materially different from those predicted here.
4. All forward-looking statements reflect knowledge and information available as of 31 July 2012 and may not be updated post publication.
5. In-licensing costs included in the model are limited to those products included in the late stage pipeline, thus in-licensing costs associated with compounds that failed prior to Phase III are not included.
6. The use of publicly available data limited the model to the use of industry average cycle times and cost allocation when calculating R&D costs over each 10 year period. This prevents an assessment of differences in development performance between each organisation, for example, therapeutic area and development programme specific cycle times are ignored and companies with better than average cycle times are not rewarded in this model.
7. Forecast R&D costs have not been included within the model beyond 31 December 2012 as accurate and relevant information is not available.
8. The assumption that average cash operating profits over the ten year historical time period equate to future margins over the 21 year revenue forecast period may fail to fully reflect the impact of recent corporate cost reduction initiatives where relevant.
9. Revenue forecasts have been risk adjusted using historical phase III and submission success rates that may not model potential future changes in the regulatory and payer environment.
10. The model is sensitive to the distribution of compounds across the late stage pipeline (phase III to submission) and as this drives cash flow timing, a snapshot taken in a different year could generate different results.
11. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of patents, marketing exclusivity or trademarks; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic alliances will be unsuccessful; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of failure to manage a crisis; the risk of delay to new product launches; the difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; the risk of environmental liabilities; the risks associated with conducting business in emerging markets; the risk of reputational damage; and the risk of product counterfeiting. Nothing in this document should be construed as a profit forecast.

# Notes

1. See <http://www.the.sgc.org/>
2. See [www.nature.com/news/drug-firm-to-share-raw-trial-data-1.11604](http://www.nature.com/news/drug-firm-to-share-raw-trial-data-1.11604)
3. GSK opens up data to advance R&D and transparency, *PharmaTimes*, 11 October 2012.
4. See <http://www.jnj.com/connect/news/all/johnson-and-johnson-announces-plans-to-establish-innovation-centers>
5. See <http://www.gsk.com/partnerships/innovation-and-investment.html>
6. See <http://www.businessweekly.co.uk/biomedtech-/13519-az-sets-up-virtual-neuroscience-unit-in-cambridge>
7. See <http://astrazeneca.com>
8. See [http://www.roche.com/research\\_and\\_development/r\\_d\\_overview/innovation\\_network.htm](http://www.roche.com/research_and_development/r_d_overview/innovation_network.htm)
9. See <http://www.bayer.com/en/news-detail-research.aspx?newsid=16309>
10. See <http://www.ehr4cr.eu/index.cfm>
11. See <http://pacerhealth.org/approach/>
12. See <http://www.transformproject.eu/>
13. See <http://www.transceleratebiopharmainc.org/>
14. The value of drug repositioning in the current pharmaceutical market, *Drug News & Perspectives* 22(2), p119-25, 2009.
15. Drug repurposing programmes get lift off, *Nature Reviews Drug Discovery* 11(7), p505-6, 2012.

# Glossary

**Average R&D cost per asset:** the average cost to develop a compound from discovery to commercialisation. Calculated by risk-adjusting the average expenses (outflow) per asset by phase III and submission success rates.

**Cohort:** the top 12 research-based pharmaceutical and biotechnology companies, measured by R&D spend in the 2008-09 financial year.

**Commercial success:** level of success exhibited by each company in terms of its ability to progress compounds through late stage development to launch. Commercial success is determined by two key events; loss of compounds from the late stage pipeline due to terminations and exit of compounds from late stage pipeline due to successful product approval and launch.

**Cost phasing:** refers to the use of pharmaceutical industry average R&D cycle times and R&D cost allocation when calculating R&D cost over the historical 10 year period to 31 December 2010, 2011 or 2012.

**Dynamic IRR:** IRR calculated over a number of years (2010-11, 2011-12 or 2010-12) to provide analysis of IRR trends over time.

**Dynamic returns:** reconcile the movement between snapshot or *yearly performance returns*.

**Existing compounds:** Existing compounds are those that appear in a company's late stage pipeline for a given year, and remain within the late stage pipeline for the next year. The revenue forecasts associated with the compound may have changed between the time periods under review due to additional information being available on the compound and/or its indication.

**Inflows:** Forecast sales that each company's late stage pipeline is estimated to generate, less cost of goods sold and other administrative expenses. Determined by applying an average cash operating margin to *risk adjusted revenues* over the 21 year forecast period.

**Internal rate of return (IRR):** a profitability measure which equates the cost of an investment and the expected benefits that the investment will deliver. IRR is calculated on a net present value basis, and is the discount rate which makes the net present value of the cash flows expected for an investment equal to zero.

**Late stage pipeline:** the basket of compounds for each company that are in either phase III clinical development or submitted for approval as of 1 January for a given year (2010, 2011 or 2012).

**Late stage terminations:** compounds whose development has been terminated or failed in phase III or submission through either regulatory rejection (regulatory terminated) or as a consequence of an internal company decision (self terminated).

**Licensing/in-licensing costs:** costs associated with the licensing-in of compounds to the late stage pipeline. This data has been sourced from the public domain. Upfront payments are included in the relevant year of acquisition. Publicly available data typically does not include the timing and amount of future contingent payments, therefore the maximum potential amounts of these costs has been applied to the product's first year of forecast sales.

**Margin:** the average cash operating margin has been calculated using reported operating profit over the ten years prior to the relevant year (2010, 2011 or 2012). R&D expense and depreciation/amortisation have been added back, capital expenditure and non-recurring costs have been deducted. Future margins over the 21 year revenue forecast period are assumed to equate average cash operating profits over the ten year period under investigation.

**Late stage pipeline refresh:** the sum of increased revenue forecasts due to new products entering the *late stage pipeline* and changes to revenue forecasts for existing late stage compounds.

**New compounds:** New compounds are those that appear in a company's late stage pipeline for a given year, but were not part of the late stage pipeline the previous year.

**Outflows:** total expenses which have been invested to develop a company's basket of late stage pipeline compounds. Outflows include both R&D costs, sourced from company profit and loss accounts, and non-cash expenses which have been disclosed, for example licensing-in costs.

**Pipeline momentum:** one of the dimensions of *dynamic IRR or dynamic returns*. Pipeline momentum explains the changes in forecast revenue from one snapshot IRR to another and is a combination of *commercial success* and *late stage pipeline refresh*.

**Product approvals:** compounds which were included in a company's late stage pipeline in a given year, but in the following year received regulatory approval and launched in at least one major market.

**Regulatory terminated compounds:** compounds that were part of a company's late stage pipeline in a given year, but which are no longer included as they were rejected by regulatory authorities the following year. Future revenues derived from these compounds are not included in the static IRR calculation for subsequent years.

**Risk adjusted revenues:** calculated by applying a *success factor* to forecast sales revenue for each company's late stage pipeline. This takes into account the likelihood of compounds progressing from phase III to submission, and submission to launch.

**R&D cost:** calculated using company R&D expenses reported in company profit and loss accounts.

**Self-terminated compound:** a compound that was part of a company's late stage pipeline in the 2010 or 2011 analysis, but which is no longer included due to the company's decision to terminate its development. Future revenues derived from such compounds are not included in the static IRR calculation for subsequent years.

**Static IRR:** IRR calculated for a given year (2010, 2011 or 2012), to provide a yearly snapshot of IRR performance. Calculated on the *late stage pipeline* as of 1 January each year, using 10 years of historical cash outflows and 21 years of forecast annual cash inflows

**Success factor:** factor calculated to reflect the probability of success for each company's *late stage pipeline*. Uses a combination of phase III and submission success rates across the *late stage pipeline*.

**Tax rates:** company-specific tax rates have been calculated based on average effective tax rates over the 10 years to either 31 December 2010, 2011 or 2012, adjusted for non-recurring items such as litigation costs, impairments, in-process R&D expense.

# Contacts

## Deloitte

### Julian Remnant

Partner, EMEA R&D Advisory Lead  
+44 (0)20 7303 3303  
jremnant@deloitte.co.uk

### Simon Hammett

Partner, EMEA Healthcare and Life Sciences Lead  
+44 (0)20 7303 6402  
shammett@deloitte.co.uk

### Dan Baker

Life Sciences Director  
+44 (0)1727 885010  
danielbaker@deloitte.co.uk

### Karen Taylor

Director  
Centre for Health Solutions  
+44 (0)20 7007 3680  
kartaylor@deloitte.co.uk

### Karen Young

Senior Manager  
Centre for Health Solutions  
+44 (0)20 7007 9457  
karyoung@deloitte.co.uk

## Deloitte contributors

We would like to acknowledge the significant contribution received from Alexandre Hermer (Research Analyst, Centre for Health Solutions). We would also like to thank Mark Stockbridge, Seb Butter, Stephen Campbell, Pooya Alai, John Tilley, Matthew Chisambi, Hans-Kristian Bryn, Stephen Gunnigle.

## Thomson Reuters

### John Cole

Solutions Director, IP & Science  
Life Sciences Professional Services  
+44 (0)20 7433 4313  
john.cole@thomsonreuters.com

### Kiran Meekings

Practice Area Consultant, Life Sciences Professional Services  
+44 (0)20 7433 4302  
kiran.meekings@thomsonreuters.com

## Thomson Reuters contributors

Tsz Tsang, Adam Somauroo

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited ("DTTL"), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see [www.deloitte.co.uk/about](http://www.deloitte.co.uk/about) for a detailed description of the legal structure of DTTL and its member firms.

Deloitte LLP is the United Kingdom member firm of DTTL.

This publication has been written in general terms and therefore cannot be relied on to cover specific situations; application of the principles set out will depend upon the particular circumstances involved and we recommend that you obtain professional advice before acting or refraining from acting on any of the contents of this publication. Deloitte LLP would be pleased to advise readers on how to apply the principles set out in this publication to their specific circumstances. Deloitte LLP accepts no duty of care or liability for any loss occasioned to any person acting or refraining from action as a result of any material in this publication.

© 2012 Deloitte LLP. All rights reserved.

Deloitte LLP is a limited liability partnership registered in England and Wales with registered number OC303675 and its registered office at 2 New Street Square, London EC4A 3BZ, United Kingdom. Tel: +44 (0) 20 7936 3000 Fax: +44 (0) 20 7583 1198.

Designed and produced by The Creative Studio at Deloitte, London. 23114A

Member of Deloitte Touche Tohmatsu Limited